Related Experiment Video
Updated: Apr 29, 2026

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement
Published on: December 11, 2017
Outcomes of surgical aortic valve replacement: the benchmark for percutaneous therapies
Pietro Bajona1, Rakesh M Suri1, Kevin L Greason1
1Division of Cardiovascular Surgery, Department of Surgery, Mayo Clinic, Rochester, MN.
Insights
Transcatheter aortic valve replacement (TAVR) offers an alternative for severe aortic stenosis (AS) patients previously deemed inoperable. Outcomes for TAVR in high-risk AS patients show benefits, with intermediate-risk data pending clinical trials.
Area of Science:
- Cardiology
- Interventional Cardiology
- Valvular Heart Disease
Background:
- Severe senile calcific aortic stenosis (AS) historically excluded many patients from surgical aortic valve replacement (SAVR) due to high perceived operative risks.
- These patients were often classified as 'high risk' or 'inoperable' for SAVR.
- The advent of transcatheter aortic valve replacement (TAVR) provides a new treatment avenue and necessitates re-evaluation of risk assessment strategies.
Purpose of the Study:
- To examine current outcomes for surgical aortic valve replacement (SAVR) in high- and intermediate-risk patients with aortic stenosis (AS).
- To use SAVR outcomes as a benchmark for evaluating emerging percutaneous therapies like transcatheter aortic valve replacement (TAVR).
- To discuss the evolving role of TAVR in managing AS across different risk strata.
Main Methods:
- Review of current literature and clinical outcomes data for SAVR in high- and intermediate-risk AS populations.
- Comparative analysis of SAVR results with emerging data on TAVR efficacy and safety.
- Discussion of risk stratification algorithms in the context of new treatment options.
Main Results:
- TAVR has demonstrated benefits in high-risk AS patients.
- The efficacy of TAVR in intermediate-risk AS patients is still under investigation, awaiting results from ongoing clinical trials.
- SAVR remains a critical consideration for specific patient groups, providing a basis for comparison.
Conclusions:
- TAVR is a viable alternative for high-risk patients with severe aortic stenosis (AS).
- Further clinical trials are essential to clarify the role and outcomes of TAVR in intermediate-risk AS patients.
- SAVR outcomes serve as an important reference point for assessing the progress of percutaneous valve therapies.
Abstract:
Historically, many patients with severe senile calcific aortic valve stenosis (AS) were not offered surgery, largely due to the perception that the risks of operation were prohibitive. Such patients have subsequently been formally designated as 'high risk' or 'inoperable' with respect to their suitability for surgical aortic valve replacement (SAVR) in the evolving lexicon of heart valve disease. The recent availability of transcatheter aortic valve replacement (TAVR) represents an alternative treatment option, and permits the opportunity to re-examine algorithms for assessing operative risk. As the experience with TAVR grows, expanded use in new patient populations can be anticipated. While TAVR in high risk AS patients has demonstrated benefits, the emerging indication in intermediate AS is less clear and conclusions will necessarily await the availability of results from ongoing clinical trials. This article will discuss current outcomes for SAVR among high- and intermediate-risk patients with AS as a barometer in assessing the results of nascent percutaneous therapies.
More Related Videos
Related Concept Videos
Aortic Regurgitation III: Medical Management
Aneurysm IV: Nursing Management
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Aortic Regurgitation I: Introduction
Aortic Regurgitation IV: Nursing Management
Aneurysm III: Interprofessional Care

